LoDoCo2 Showed Low-Dose Colchicine Reduced MACE in Men with ASCVD. Here Is the Residual Inflammatory Risk Evidence.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

James is 57 years old. He is a project manager for a utility company in Columbus, Ohio, and he has done everything right, by most cardiologists’ standards, at least. He had a non-ST-elevation myocardial infarction (NSTEMI) four years ago, underwent percutaneous coronary intervention with a drug-eluting stent to his mid-LAD, and has been adherent to his medical regimen ever since: rosuvastatin 40 mg, ezetimibe 10 mg, aspirin 81 mg, and a beta-blocker. His LDL at last check was 48. His ApoB was 62.

And yet.

His hs-CRP at his last annual visit was 2.4 mg/L. His cardiologist had mentioned this in passing, “your CRP is a little raised but your cholesterol is great”, and moved on. James came to me asking a different question: “My cholesterol is great. My blood pressure is perfect. My LDL is 48. Why do I still feel like I’m going to have another heart attack?”

The answer to that question has a name: residual inflammatory risk.

The CANTOS trial (Ridker et al., 2017, NEJM) was the study that forced cardiology to confront what the ApoB-lowering era had not fully solved. In CANTOS, canakinumab (a biologic inhibitor of IL-1beta, an inflammatory cytokine) reduced major adverse cardiovascular events by 15% in patients with prior MI and raised hs-CRP, independent of any lipid-lowering effect 5 / Solid . The drug confirmed that residual inflammatory risk, measured by hs-CRP above 2.0 mg/L, is a real, addressable cardiovascular risk factor in its own right, not just a biomarker.

CANTOS also confirmed that the IL-1beta/IL-6/NLRP3 inflammasome pathway is a causal mechanism in atherosclerotic plaque progression and instability. The pathway that canakinumab targeted is the same pathway targeted by colchicine.

Colchicine has been used in medicine for 3,500 years, primarily for gout. At 0.5 mg daily, the Lodoco dose, it is a potent, inexpensive, oral anti-inflammatory that specifically suppresses the NLRP3 inflammasome. The LoDoCo2 trial showed a 31% relative reduction in the composite of cardiovascular death, nonfatal MI, nonfatal stroke, and ischemia-driven revascularization in patients with chronic coronary disease 5 / Solid . The FDA approved Lodoco in June 2023.

James’s question was answered: his hs-CRP at 2.4 puts him in the residual inflammatory risk category. And there is now a drug, at $3 per month (generic colchicine) to several hundred dollars per month (Lodoco branded), that directly targets the mechanism responsible for his raised risk, without touching his lipids at all.

I started the Lodoco conversation before he left.

Methodology Note

This article draws from the FDA-approved prescribing information for Lodoco (colchicine 0.5 mg tablets; NDA 216983, Agepha Pharma, approved June 19, 2023), the published RCT corpus listed in the References section, and real-world evidence from peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, and European Heart Journal. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article.

What Lodoco Is, FDA Approval Status and Indication

The drug

Lodoco is colchicine 0.5 mg formulated as a once-daily oral tablet for cardiovascular risk reduction. It is manufactured by Agepha Pharma (the branded Lodoco product as approved in Australia and subsequently in the United States under NDA 216983). Generic colchicine 0.5 mg is available separately; the Lodoco brand formulation is what was used in the pivotal LoDoCo2 trial.

FDA approval: NDA 216983, approved June 19, 2023, making Lodoco the first FDA-approved oral anti-inflammatory specifically for chronic coronary disease risk reduction. This is a milestone in cardiology: the first drug approved not for lipid modification, blood pressure reduction, or antiplatelet effect, but specifically for the anti-inflammatory pathway in atherosclerotic cardiovascular disease.

FDA-approved indication (verbatim from USPI):

“Lodoco (colchicine) tablets are indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic cardiovascular disease (ASCVD) or with multiple risk factors for cardiovascular disease.”

The indication covers two populations:

1. Patients with established ASCVD (prior MI, prior stroke, coronary artery disease, peripheral arterial disease)
2. Patients with multiple cardiovascular risk factors without established disease (primary prevention in high-risk individuals)

This is a broad indication. It means Lodoco is not just for post-MI patients like James. It is also for the man with multiple cardiovascular risk factors (hypertension, dyslipidemia, diabetes, smoking, obesity) who has not yet had a cardiac event.

What Lodoco is not

Lodoco is not a treatment for gout (though colchicine at different doses is the standard treatment for acute gout flares and gout prophylaxis). Lodoco is not a treatment for pericarditis (colchicine at different doses is the standard treatment). Lodoco 0.5 mg is the cardiovascular-specific formulation at the dose validated in the LoDoCo2 trial. The pericarditis dose (0.5 mg twice daily), the gout prophylaxis dose (0.6 mg once or twice daily), and the acute gout dose (1.2 mg followed by 0.6 mg one hour later) are all different indications with different dosing regimens.

A man already on colchicine for gout prophylaxis (typically 0.6 mg daily as Colcrys) who also has ASCVD is not automatically covered by the Lodoco cardiovascular indication at that dose, the LoDoCo2 trial used 0.5 mg daily, not 0.6 mg. This distinction matters for prescribing precision, though the clinical significance of the 0.1 mg difference is uncertain.

The AHA/ACC 2023 guideline position

The 2023 ACC Expert Consensus Decision Pathway for Management of Patients with Stable Ischemic Heart Disease incorporated colchicine as a Class IIa recommendation (moderate benefit, reasonable to use) for cardiovascular risk reduction in patients with chronic coronary disease who are already on statin and antiplatelet therapy 5 / Solid . This is the first time colchicine has appeared in ACC cardiovascular risk reduction guidelines at this level of recommendation.

The Mechanism, How It Works

The NLRP3 inflammasome pathway

To understand why Lodoco matters, you need to understand what residual inflammatory risk is at the molecular level.

Atherosclerosis is not just a plumbing problem. It is an inflammatory disease. Lipids deposited in the arterial wall (the ApoB-containing lipoproteins: LDL, IDL, Lp(a)) are not the only drivers of plaque progression and rupture. The immune response to those deposited lipids is equally important, and in some patients, especially those with raised hs-CRP despite target lipid management, the immune response has become dysregulated in a way that perpetuates plaque vulnerability independently of ongoing lipid accumulation 5 / Solid .

The NLRP3 inflammasome is a multi-protein complex in macrophages and other immune cells that acts as a molecular sensor for cellular danger signals, including cholesterol crystals, oxidized LDL, and uric acid crystals. When activated, the NLRP3 inflammasome catalyzes the cleavage of pro-interleukin-1beta (pro-IL-1beta) to its active form, IL-1beta. IL-1beta is the master upstream inflammatory cytokine in the atherosclerotic plaque’s inflammatory cascade: it drives IL-6 production, which drives CRP production, which drives the fibrinogen and clotting factor upregulation that makes plaques thrombogenic 5 / Solid .

How colchicine suppresses the NLRP3 inflammasome

Colchicine works through two primary anti-inflammatory mechanisms relevant to cardiovascular disease:

1. Microtubule disruption: Colchicine binds to tubulin and prevents its polymerization into microtubules. Microtubule assembly is essential for NLRP3 inflammasome assembly. Without microtubule function, the NLRP3 complex cannot oligomerize and activate caspase-1 to cleave IL-1beta 5 / Solid 60515-9).

2. Neutrophil migration inhibition: Colchicine inhibits neutrophil rolling and adhesion to the vascular endothelium, and reduces neutrophil L-selectin surface expression. Neutrophils are key early responders in the inflammatory cascade within atherosclerotic plaques. Reduced neutrophil trafficking to the plaque reduces the local inflammatory milieu that promotes plaque vulnerability 5 / Solid .

The net result: colchicine at 0.5 mg daily suppresses the NLRP3/IL-1beta/IL-6 inflammatory cascade in a way that reduces plaque inflammation, reduces plaque vulnerability, and reduces the risk of the inflammatory trigger that converts a stable plaque to an unstable one causing a clinical event.

The ApoB and inflammation distinction

James’s case illustrates the clinical distinction: ApoB drives lipid deposition in the arterial wall. Inflammation determines whether that deposited lipid causes a plaque rupture. A man with ApoB at 62 (well-controlled on rosuvastatin and ezetimibe) but hs-CRP at 2.4 has addressed the lipid driver but not the inflammatory driver. Lodoco addresses the inflammatory driver directly, without affecting lipid levels 5 / Solid .

This is the “Ridker two-pathway” framework that CANTOS established: the atherosclerotic event rate in at target treated patients (statin + antiplatelet) can be predicted by two independent residual risk drivers, residual ApoB (measured by non-HDL cholesterol or ApoB) and residual inflammation (measured by hs-CRP). Lodoco addresses the inflammatory pathway. PCSK9 inhibitors, ezetimibe, and high-intensity statins address the ApoB pathway. In the man with improved ApoB and raised hs-CRP, Lodoco is the next logical pharmacological intervention.

The Trial Data, What the RCTs Show

LoDoCo2, the anchor trial

LoDoCo2 (Nidorf et al., 2020, NEJM): 5,522 patients with chronic coronary disease (established CAD, either by history of MI, stable angina with angiographic evidence, or prior coronary revascularization), randomized to colchicine 0.5 mg daily or placebo. Baseline: all patients were on target medical therapy (statin and antiplatelet therapy). Median follow-up: 28.6 months.

Primary endpoint: Composite of cardiovascular death, nonfatal spontaneous MI (excluding procedure-related MI), nonfatal stroke, or ischemia-driven coronary revascularization.

Results:

• Primary endpoint event rate: 6.8% colchicine versus 9.6% placebo.
• Hazard ratio: 0.69 (95% CI 0.57 to 0.83, p < 0.001).
• Relative risk reduction: 31%.
• Absolute risk reduction: 2.8% over 28.6 months.
• Number needed to treat (NNT): approximately 36 patients over 28.6 months to prevent one primary composite event 5 / Solid .

The LoDoCo2 result is one of the most clinically significant cardiovascular outcomes of the 2020s. A 31% relative reduction in MACE in patients already on target lipid-lowering and antiplatelet therapy represents a substantial incremental benefit from a single, inexpensive, oral drug.

Individual endpoint results in LoDoCo2:

• Spontaneous MI: HR 0.70 (95% CI 0.53 to 0.93), 30% relative reduction 5 / Solid
• Ischemia-driven revascularization: HR 0.75 (95% CI 0.60 to 0.94), 25% relative reduction 5 / Solid
• Stroke: HR 0.67 (95% CI 0.44 to 1.01), 33% relative reduction, nominally non-significant at p = 0.06 5 / Solid
• Cardiovascular death: HR 0.83 (95% CI 0.47 to 1.47), directional benefit, not statistically significant 5 / Solid

Safety in LoDoCo2: The principal safety finding was non-cardiovascular death, which was numerically higher in the colchicine group (HR 1.51, 95% CI 0.99 to 2.31, p = 0.06). This finding has been extensively reviewed and discussed. The excess non-cardiovascular deaths in the colchicine group were heterogeneous (infections, cancer, accidents) and did not show a consistent biological pattern suggesting drug causation. Subsequent analyses and the COLCOT trial did not replicate a non-cardiovascular death signal. The FDA concluded that the benefit-risk profile supported approval. The non-cardiovascular death observation requires acknowledgment but should not be used to contraindicate colchicine in appropriate patients 5 / Solid .

COLCOT, the post-MI trial

COLCOT (Tardif et al., 2019, NEJM): 4,745 patients randomized within 30 days of an MI to colchicine 0.5 mg daily or placebo. All patients were on target medical therapy. Median follow-up: 22.6 months.

Primary endpoint: Composite of cardiovascular death, resuscitated cardiac arrest, nonfatal MI, nonfatal stroke, or urgent hospitalization for angina leading to coronary revascularization.

Results:

• Primary endpoint event rate: 5.5% colchicine versus 7.1% placebo.
• Hazard ratio: 0.77 (95% CI 0.61 to 0.96, p = 0.02).
• Relative risk reduction: 23%.
• Absolute risk reduction: 1.6% over 22.6 months 5 / Solid .

COLCOT is the post-acute MI trial. It shows that starting colchicine 0.5 mg within 30 days of an MI, on top of guideline-directed therapy, further reduces recurrent events. For a man like James who had his MI four years ago, COLCOT establishes that the benefit of colchicine extends into the chronic phase of coronary disease (as does LoDoCo2’s chronic CAD population).

The non-cardiovascular death signal from LoDoCo2 was not replicated in COLCOT (HR for non-cardiovascular death: 0.93, 95% CI 0.55 to 1.56) 5 / Solid .

CANTOS, the inflammasome proof-of-concept

CANTOS (Ridker et al., 2017, NEJM): 10,061 patients with prior MI and hs-CRP >= 2.0 mg/L, randomized to canakinumab (anti-IL-1beta biologic) 50 mg, 150 mg, or 300 mg quarterly subcutaneous injection, or placebo.

Primary endpoint: Nonfatal MI, nonfatal stroke, or cardiovascular death.

Results at 150 mg dose:

• Hazard ratio: 0.85 (95% CI 0.74 to 0.98, p = 0.021).
• Relative risk reduction: 15% 5 / Solid .

CANTOS is the proof-of-concept trial for the inflammatory pathway in ASCVD. It confirmed that:

1. Residual inflammatory risk (measured by hs-CRP >= 2.0) is an independent, modifiable cardiac risk factor in post-MI patients on target statin therapy.
2. Suppressing the IL-1beta arm of the NLRP3 inflammasome cascade reduces MACE.
3. The benefit was concentrated in patients who achieved hs-CRP suppression on treatment, suggesting that the magnitude of inflammatory suppression correlates with cardiovascular benefit.

Canakinumab was never commercially developed for cardiovascular indications due to cost (approximately $200,000/year), infection risk, and the availability of less expensive alternatives. Colchicine targets the same pathway at $3 to $300/month depending on formulation and insurance.

The LoDoCo original trial (2013)

LoDoCo original (Nidorf et al., 2013, JACC): 532 patients with stable coronary artery disease, randomized to colchicine 0.5 mg daily or no colchicine (open-label). Over a 3-year follow-up, the colchicine group had significantly fewer acute coronary syndromes and out-of-hospital cardiac arrests 5 / Solid . This was the pilot trial that provided the mechanistic rationale for the larger LoDoCo2.

Real-World Evidence

Post-approval prescribing data on Lodoco is emerging. The FDA approval in June 2023 means real-world clinical data is still accumulating, and large observational studies with sufficient follow-up are anticipated but not yet fully published.

Early prescription trend data from US commercial and Medicare claims suggests that colchicine for cardiovascular indications is being prescribed predominantly by cardiologists (rather than primary care physicians), and predominantly in post-MI patients rather than the broader chronic coronary disease population 3 / Early . This suggests that the LoDoCo2 population, stable chronic CAD without recent acute event, is significantly undertreated with colchicine, despite the FDA indication and Class IIa guideline recommendation.

Australian prescribing data (where Lodoco was approved earlier than in the United States) shows similar patterns: the medication is used in post-MI patients at cardiology practices but remains underutilized in the stable CAD population in primary care 4 / Promising .

The cost argument for colchicine is compelling: generic colchicine 0.5 mg is available in the United States for approximately $5 to $15 per month. The Lodoco brand is substantially more expensive. For a man like James, whose medication cost burden already includes rosuvastatin, ezetimibe, aspirin, and a beta-blocker, adding generic colchicine at low cost represents the highest MACE-reduction-per-dollar value of any currently available cardiovascular agent in the chronic coronary disease setting 5 / Solid .

What It Does for the Heart, The Cardiac Signal

The cardiac signal, precisely stated

For James, whose ApoB is 62 and hs-CRP is 2.4, the cardiac benefit of Lodoco is the most direct of any pharmacotherapy currently available to him:

What the LoDoCo2 and COLCOT data shows:

• Lodoco (colchicine 0.5 mg daily) reduces the composite of cardiovascular death, MI, stroke, and revascularization by 31% in patients with chronic coronary disease on target background therapy 5 / Solid .
• Colchicine 0.5 mg daily reduces the composite of cardiovascular death, resuscitated arrest, MI, stroke, and urgent coronary revascularization by 23% in post-MI patients on target background therapy 5 / Solid .
• These benefits are independent of lipid levels. Adding colchicine to a patient with LDL 48 and ApoB 62 produces cardiovascular benefit through the inflammatory pathway, not through lipid modification.

What Lodoco does to hs-CRP: Colchicine reduces hs-CRP in patients with ASCVD 5 / Solid . The magnitude of hs-CRP reduction correlates with cardiovascular benefit in the CANTOS analysis framework 4 / Promising . In practice, I use hs-CRP as a monitoring biomarker to assess the inflammatory response to colchicine, not as a primary outcome predictor.

The ApoB-inflammation dual framework: For James, and for any man with established ASCVD and hs-CRP above 2.0:

• ApoB target: < 70 mg/dL for secondary prevention (or < 80 mg/dL by some guidelines), James is at 62, well-controlled.
• hs-CRP target: < 2.0 mg/L is the threshold where residual inflammatory risk is substantially reduced. James is at 2.4, above the threshold.
• Lodoco addresses the hs-CRP side of the equation. No lipid-lowering drug does.

The coronary calcium context

For a man in the primary prevention setting, no prior MI, no established CAD, with a CAC score above 100, raised hs-CRP, and multiple cardiovascular risk factors, the Lodoco indication (“multiple cardiovascular risk factors”) now applies. The LoDoCo2 and COLCOT populations were secondary prevention (established CAD), but the FDA indication extends to primary prevention in high-risk individuals. The 2023 ACC ECDP supports this broader application 5 / Solid .

Safety, The Full Picture

8a. No black-box warning for Lodoco

Lodoco does not carry a black-box warning in its FDA-approved prescribing information.

8b. Major warnings and precautions

Neuromuscular toxicity. Colchicine can cause myopathy and rhabdomyolysis, particularly in combination with statin therapy. The risk is low at the 0.5 mg/day dose used in Lodoco, but it is not zero. In patients on high-dose statins (rosuvastatin 40 mg, atorvastatin 80 mg), the combination with colchicine requires monitoring for unexplained muscle pain, weakness, or dark urine 5 / Solid . In LoDoCo2 and COLCOT, the clinical myopathy event rate was very low and not significantly different between colchicine and placebo at the 0.5 mg dose.

Myelosuppression. Colchicine can suppress bone marrow activity, leading to thrombocytopenia, leukopenia, and aplastic anemia at higher doses or in overdose. At 0.5 mg/day, clinically significant myelosuppression is rare 5 / Solid .

Renal impairment. Colchicine is renally cleared. The dose should be reduced in patients with eGFR < 30 mL/min/1.73m2, and colchicine is contraindicated in patients with severe renal impairment (dialysis). For patients with eGFR 30 to 60, careful monitoring and potential dose reduction to 0.5 mg every other day is appropriate 5 / Solid .

Hepatic impairment. Colchicine is hepatically metabolized (CYP3A4 and P-glycoprotein). In severe hepatic impairment, colchicine clearance is reduced and toxicity risk increases. Lodoco is not recommended in severe hepatic impairment 5 / Solid .

Drug interactions, CYP3A4 and P-glycoprotein. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) and P-glycoprotein inhibitors (cyclosporine, verapamil, diltiazem, dronedarone) can increase colchicine plasma levels substantially, increasing toxicity risk. For cardiac patients on rate-controlling medications like verapamil or diltiazem (sometimes used for atrial fibrillation), this interaction requires attention. If a strong CYP3A4 inhibitor is required, Lodoco should be temporarily discontinued if possible, or the dose reduced with careful monitoring 5 / Solid .

Statins and colchicine. The combination of colchicine with statin therapy increases the risk of myopathy above either drug alone, but the absolute risk at the Lodoco 0.5 mg dose in the LoDoCo2 trial, which enrolled patients predominantly on statin therapy, was not clinically significant in the trial population 5 / Solid .

8c. GI adverse effects

Gastrointestinal adverse effects are the most common adverse effect of colchicine. Diarrhea, nausea, abdominal cramping, and vomiting occur in a dose-dependent fashion. In LoDoCo2 at 0.5 mg daily, gastrointestinal adverse effects led to discontinuation in approximately 1% of patients, a very low rate that reflects the tolerability of the low cardiovascular dose 5 / Solid . At gout treatment doses (1.2 to 1.8 mg), GI adverse effects are substantially more common.

8d. Who should not take Lodoco

Absolute contraindications:

• Severe renal impairment (dialysis, eGFR < 15), colchicine accumulates to toxic levels
• Severe hepatic impairment
• Concurrent use of strong CYP3A4 inhibitors AND strong P-glycoprotein inhibitors (combined use prohibitively increases colchicine exposure)
• Known hypersensitivity to colchicine

Clinical situations requiring caution:

• Patients on cyclosporine (P-glycoprotein inhibitor; substantially increases colchicine levels)
• Patients on verapamil or diltiazem for rate control (P-glycoprotein inhibition; monitor for toxicity)
• Patients on clarithromycin or azithromycin courses (CYP3A4 inhibition; temporary drug hold during the antibiotic course)
• Patients with CKD stage 3b to 4 (eGFR 15 to 45), reduced dose and careful monitoring required

Clinical Decision-Making: Lodoco

The clinical decision framework

Lodoco is the most underutilized cardiovascular drug in my current practice. In a patient population where statins, aspirin, ACE inhibitors, and beta-blockers are routinely prescribed for chronic coronary disease, colchicine 0.5 mg daily, which has a Class IIa recommendation from the ACC and a 31% relative MACE reduction in LoDoCo2, is prescribed to a small minority of eligible patients.

The primary reasons it is not prescribed: (1) cardiologists and primary care physicians are accustomed to thinking about cardiovascular pharmacology in terms of lipid-lowering and blood pressure lowering, and the anti-inflammatory framework is newer; (2) the colchicine prescription habit is associated with gout and pericarditis, not coronary disease; (3) the FDA approval is from June 2023, and guideline adoption always lags by years.

The patient who most needs Lodoco: the man with established ASCVD (post-MI, stable CAD with revascularization, or CAC score above 100 with multiple risk factors) whose ApoB is already at target on statin + ezetimibe, but whose hs-CRP remains above 2.0 mg/L. That patient has residual inflammatory risk that no currently prescribed medication is addressing.

Patient selection rubric for men

1. Established ASCVD or multiple cardiovascular risk factors. The FDA indication is clear. Post-MI (like James), stable CAD, or primary prevention with multiple risk factors (hypertension + dyslipidemia + diabetes or smoking or obesity) are all covered.

2. hs-CRP status. I check hs-CRP in every patient with established ASCVD at every annual visit. hs-CRP >= 2.0 mg/L in a patient already on statin therapy identifies residual inflammatory risk. This is the phenotype for Lodoco.

3. Renal function. eGFR must be adequate (>= 30 mL/min/1.73m2) for full-dose colchicine. For eGFR 30 to 60, reduced dose or alternate-day dosing may be required.

4. Drug interaction review. Current cardiac medications for P-glycoprotein and CYP3A4 interactions: verapamil, diltiazem, dronedarone, amiodarone are P-glycoprotein inhibitors at varying degrees. Macrolide antibiotics (clarithromycin, erythromycin) are CYP3A4 inhibitors. Azole antifungals. Cyclosporine. Review the list before prescribing.

5. Statin regimen. On high-dose statin (rosuvastatin 40 mg, atorvastatin 80 mg): counsel about myopathy monitoring. Any unexplained muscle pain, weakness, or dark urine after starting Lodoco requires CK measurement and clinical evaluation.

Pre-flight checklist

• hs-CRP (to confirm residual inflammatory risk)
• eGFR/creatinine (renal dosing assessment)
• Liver function tests (hepatic clearance assessment)
• Current medication list reviewed for CYP3A4 and P-glycoprotein inhibitors
• Statin regimen documented (myopathy risk counseling)
• ApoB (to frame the residual risk picture: ApoB-pathway vs. inflammatory pathway)
• Baseline CBC if clinically indicated (myelosuppression monitoring)

Monitoring protocol

Month 1: GI tolerance assessment. Any muscle pain or weakness? If no GI adverse effects and no muscle symptoms, the medication is likely well-tolerated.

Month 3: hs-CRP measurement. If hs-CRP has fallen below 2.0 mg/L, colchicine is producing its intended anti-inflammatory effect. If hs-CRP remains above 2.0, the drug is still appropriate (LoDoCo2 benefit was not conditioned on hs-CRP suppression in the primary analysis), but the degree of inflammatory modulation can inform shared decision-making.

Month 6 and annually: hs-CRP, ApoB, renal function. Annual review of the drug interaction list (medications change over time).

Antibiotic course management: When a cardiac patient on Lodoco is prescribed clarithromycin or azithromycin by a different provider (upper respiratory infection, dental procedure), I educate patients proactively: if clarithromycin is prescribed, hold Lodoco for the duration of the antibiotic course and for 48 hours after completing it. Azithromycin has less CYP3A4 inhibition than clarithromycin; a dose reduction or brief hold during azithromycin courses is prudent 5 / Solid .

The ApoB-first, then Lodoco framework

This clinical framework for the man with established ASCVD:

Step 1: ApoB to target. Secondary prevention target is ApoB < 70 mg/dL, or < 80 mg/dL per some guidelines. High-intensity statin + ezetimibe is the first-line approach. PCSK9 inhibitor if ApoB remains above target.

Step 2: Blood pressure to target. Systolic < 130 mmHg in established ASCVD (per AHA/ACC 2017 guidelines).

Step 3: Antiplatelet therapy. Aspirin 81 mg/day in established ASCVD. P2Y12 inhibitor after recent ACS per guideline duration.

Step 4: Check hs-CRP. If ApoB is at target, blood pressure is at target, antiplatelet is in place, and hs-CRP remains > 2.0: add Lodoco.

This is the framework in which colchicine becomes the logical next step. Not the first step. The fourth step. But a step that many cardiologists are currently skipping.

What to Do Now

Four concrete next steps for the man with established ASCVD or high cardiovascular risk:

Step 1: Get an hs-CRP measured. Ask your cardiologist or primary care physician at your next visit: “I want a high-sensitivity C-reactive protein (hs-CRP) level checked. I am trying to understand whether I have residual inflammatory risk on top of my lipid management.” This is a standard lab test, covered by most insurance plans, that takes one blood draw. If your hs-CRP is >= 2.0 mg/L despite target statin therapy, you have a modifiable residual risk that may warrant Lodoco.

Step 2: Ask about Lodoco if your hs-CRP is raised. The specific conversation: “My hs-CRP is above 2.0. The LoDoCo2 trial showed that colchicine 0.5 mg daily reduces major cardiovascular events by 31% in patients with chronic coronary disease on target therapy. The FDA approved Lodoco for exactly this indication in June 2023. Is this appropriate for me?” A cardiologist who has read the 2023 guidelines and the LoDoCo2 trial will have a direct answer.

Step 3: Review your current medications for interactions. If you take verapamil, diltiazem, or dronedarone for heart rate control; if you take cyclosporine; or if you are frequently prescribed clarithromycin for respiratory infections, these require a specific conversation with your prescriber before starting Lodoco about drug interaction management.

References

1. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465-1479. DOI: 10.1016/j.clinthera.2014.07.017

2. Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. DOI: 10.1038/s41572-019-0106-z

3. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. DOI: 10.1016/j.jacc.2012.10.027

4. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med. 2020;383(19):1838-1847. DOI: 10.1056/NEJMoa2021372

5. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131. DOI: 10.1056/NEJMoa1707914

6. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med. 2019;381(26):2497-2505. DOI: 10.1056/NEJMoa1912388

7. U.S. Food and Drug Administration. Lodoco (colchicine) 0.5 mg tablets prescribing information. NDA 216983. Agepha Pharma. Approved June 19, 2023. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216983s000lbl.pdf

8. Writing Committee, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. J Am Coll Cardiol. 2022;79(2):197-215. DOI: 10.1016/j.jacc.2021.09.005

— Dr. Job Mogire, MD FACP FACC Carle Foundation Hospital | Carle Illinois College of Medicine faculty Stop Dying Early | stopdyingearly.com

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.